Cartesian reports 100% LLDAS response in Phase 2 SLE; expands Descartes-08 into myositis

Cartesian Therapeutics, Inc.

100% LLDAS response at Month 3 (n=3) in Phase 2 SLE trial; 2 of 3 achieved DORIS remission.
No CRS or ICANS observed; outpatient administration without lymphodepleting chemotherapy.
Plans to pause SLE and Descartes-15 (multiple myeloma) to prioritize MG Phase 3 and myositis.
Myositis seamless adaptive Phase 2 trial expected to start 1H26; IND filing by end 2025.
Cash runway extended to mid-2027 supporting MG Phase 3 and myositis trial initiation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.